BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17096324)

  • 1. Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer.
    Johansson M; McKay JD; Stattin P; Canzian F; Boillot C; Wiklund F; Adami HO; Bälter K; Grönberg H; Kaaks R
    Int J Cancer; 2007 Feb; 120(3):539-42. PubMed ID: 17096324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
    Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
    J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels.
    Johansson M; McKay JD; Wiklund F; Rinaldi S; Verheus M; van Gils CH; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4820-6. PubMed ID: 17911177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort.
    Cheng I; Stram DO; Penney KL; Pike M; Le Marchand L; Kolonel LN; Hirschhorn J; Altshuler D; Henderson BE; Freedman ML
    J Natl Cancer Inst; 2006 Jan; 98(2):123-34. PubMed ID: 16418515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
    Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk.
    McKay JD; Kaaks R; Johansson M; Biessy C; Wiklund F; Bälter K; Adami HO; Boillot C; Gioia-Patricola L; Canzian F; Stattin P; Grönberg H
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):169-73. PubMed ID: 17220348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
    Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
    Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in the COX-2 gene and the association with prostate cancer risk.
    Shahedi K; Lindström S; Zheng SL; Wiklund F; Adolfsson J; Sun J; Augustsson-Bälter K; Chang BL; Adami HO; Liu W; Grönberg H; Xu J
    Int J Cancer; 2006 Aug; 119(3):668-72. PubMed ID: 16506214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk.
    Terry KL; Tworoger SS; Gates MA; Cramer DW; Hankinson SE
    Carcinogenesis; 2009 Dec; 30(12):2042-6. PubMed ID: 19858071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk.
    Lindmark F; Zheng SL; Wiklund F; Bälter KA; Sun J; Chang B; Hedelin M; Clark J; Johansson JE; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
    Br J Cancer; 2005 Aug; 93(4):493-7. PubMed ID: 16106254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).
    Patel AV; Cheng I; Canzian F; Le Marchand L; Thun MJ; Berg CD; Buring J; Calle EE; Chanock S; Clavel-Chapelon F; Cox DG; Dorronsoro M; Dossus L; Haiman CA; Hankinson SE; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Linseisen J; Lund E; Manjer J; McCarty C; Peeters PH; Pike MC; Pollak M; Riboli E; Stram DO; Tjonneland A; Travis RC; Trichopoulos D; Tumino R; Yeager M; Ziegler RG; Feigelson HS;
    PLoS One; 2008 Jul; 3(7):e2578. PubMed ID: 18596909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer.
    Al-Zahrani A; Sandhu MS; Luben RN; Thompson D; Baynes C; Pooley KA; Luccarini C; Munday H; Perkins B; Smith P; Pharoah PD; Wareham NJ; Easton DF; Ponder BA; Dunning AM
    Hum Mol Genet; 2006 Jan; 15(1):1-10. PubMed ID: 16306136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer.
    Pechlivanis S; Wagner K; Chang-Claude J; Hoffmeister M; Brenner H; Försti A
    Cancer Detect Prev; 2007; 31(5):408-16. PubMed ID: 18031946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk.
    Gaudet MM; Chanock S; Lissowska J; Berndt SI; Peplonska B; Brinton LA; Welch R; Yeager M; Bardin-Mikolajczak A; Garcia-Closas M
    Cancer Res; 2006 Oct; 66(19):9781-5. PubMed ID: 17018638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer.
    Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J
    J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk.
    Stevens VL; Hsing AW; Talbot JT; Zheng SL; Sun J; Chen J; Thun MJ; Xu J; Calle EE; Rodriguez C
    Int J Cancer; 2008 Dec; 123(11):2644-50. PubMed ID: 18752252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy.
    Chang CF; Pao JB; Yu CC; Huang CY; Huang SP; Yang YP; Huang CN; Chang TY; You BJ; Lee HZ; Hour TC; Bao BY
    Ann Surg Oncol; 2013 Jul; 20(7):2446-52. PubMed ID: 23397154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotype effect in the IGF1 promoter accounts for the association between microsatellite and serum IGF1 concentration.
    Chen HY; Chan IH; Sham AL; Leung VH; Ma SL; Ho SC; Tang NL
    Clin Endocrinol (Oxf); 2011 Apr; 74(4):520-7. PubMed ID: 21198739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.
    Haiman CA; Stram DO; Cheng I; Giorgi EE; Pooler L; Penney K; Le Marchand L; Henderson BE; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1021-5. PubMed ID: 16702386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.